Results 21 to 30 of about 393,422 (164)
Pan-p63 but not ΔNp63 (p40) expression in undifferentiated carcinoma of the pancreas
Undifferentiated carcinoma of the pancreas (UC) is a carcinoma without a definitive direction of differentiation. Tumour protein p63 is a regulator of squamous phenotype, which may also be engaged in tumour development.
Łukasz Liszka
doaj +1 more source
Pancreatic neuroendocrine neoplasms (PanNENs) are the neuroendocrine neoplasms with greatest rate of increase in incidence. Approximately 10% of PanNENs arise as inherited tumour syndromes which include multiple endocrine neoplasia type 1, multiple ...
Lam, Alfred King-yin, Ishida, Hirotaka
core +1 more source
The rare case of a cystic pancreatic neuroendocrine tumor
The pancreatic neuroendocrine tumors (PanNETs) most commonly present as solid neoplasms; however, very rarely, they may present primarily as cystic neoplasms. Most of the cystic PanNETs are non-secreting tumors, and the radiological features are not well
Tarun Kumar +3 more
doaj
Post-surgical Pancreatitis Masquerading as Recurrent Neuroendocrine Cancer [PDF]
Neuroendocrine tumours of the pancreas can have a spectrum of behaviour from relatively benign to aggressive. Resection can result in cure although metastatic disease is described.
Oniscu, Anca +5 more
core +1 more source
Background Calcitonin-producing pancreatic neuroendocrine neoplasms (PanNENs) are extremely rare. There have been no reports of a patient in whom liver metastases were the presenting finding, and a calcitonin-producing PanNEN was subsequently detected ...
Ryusei Yamamoto +6 more
doaj +1 more source
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Brand, Stephan +8 more
core +1 more source
Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3 [PDF]
Pancreatic neuroendocrine neoplasms (PanNENs) are rare tumours that compose 1-2% of all pancreatic tumours. Patients with metastatic grade 3 neoplasia are usually treated with chemotherapy but have a poor progression-free and overall survival.
Eva Tiensuu Janson +21 more
core +2 more sources
Characterization of the neuroendocrine pancreatic tumors nature by MDCT enhancement pattern: a radio-pathological correlation [PDF]
Introduction Pre-operative suspicion of neuroendocrine pancreatic lesions nature arises both from clinical (presence and the type of secreted hormone) and imaging findings.
NOVARIA, LISA
core +1 more source
Consensus on the clinical diagnosis and treatment of grade 3 pancreatic neuroendocrine tumors
The World Health Organization (WHO) 2017 classifications for neuroendocrine neoplasms (NENs) subdivided grade 3 pancreatic neuroendocrine neoplasms (pNENs) into G3 well-differentiated pancreatic neuroendocrine tumors (G3 pNETs) and poorly differentiated ...
Jie Chen +22 more
doaj +1 more source
Background Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN) of the pancreas are extremely rare. Their pathogenesis and molecular landscape are largely unknown.
Jingci Chen +3 more
doaj +1 more source

